Gyre Therapeutics (GYRE) financial statements
Gyre Therapeutics reported revenue of $117M in fiscal 2025, up 80.9% a year over 8 years.
Net income was $5M.
Free cash flow was -$180,000.
The diluted share count rose 13142% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Gyre Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1M | $6,000 | — | $21M | $7M | $102M | $113M | $106M | $117M |
| Cost of revenue | — | — | — | — | — | — | $5M | $5M | $4M | $5M |
| Gross profit | — | — | — | — | — | — | $97M | $109M | $102M | $111M |
| Research and development | $12M | $13M | $21M | $44M | $53M | $69M | $17M | $14M | $12M | $14M |
| Selling, general and admin | $9M | $10M | $12M | $13M | $16M | $19M | $72M | $76M | $74M | $86M |
| Operating income | -$20M | -$22M | -$34M | -$57M | -$57M | -$88M | $9M | -$67M | $16M | $11M |
| Pre-tax income | — | — | — | — | — | -$88M | $9M | -$77M | $23M | $14M |
| Income tax | — | — | — | — | — | — | $5M | $9M | $5M | $5M |
| Net income | -$17M | -$22M | -$30M | -$55M | -$56M | -$88M | -$8M | -$93M | $12M | $5M |
| EPS (diluted) | -$21.75 | -$7.45 | -$2.68 | -$4.60 | -$2.93 | -$2.87 | $0.03 | -$1.41 | $0.05 | $0.02 |
| Diluted shares | 1M | 3M | 11M | 12M | 19M | 31M | 76M | 66M | 102M | 103M |
| Gross margin | — | — | — | — | — | — | 95.3% | 95.9% | 96.3% | 95.4% |
| Operating margin | — | -2143.6% | -563700.0% | — | -273.9% | -1197.8% | 9.0% | -59.3% | 15.3% | 9.9% |
| Net margin | — | -2118.0% | -500916.7% | — | -268.5% | -1198.3% | -8.1% | -81.9% | 11.4% | 4.3% |
Balance sheet
Fiscal years, from Gyre Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $17M | $32M | $120M | $77M | $82M | $47M | $22M | $34M | $27M | $65M |
| Receivables | — | — | — | $15M | $3M | $2M | — | $15M | $20M | $31M |
| Inventory | — | — | — | — | — | — | $6M | $4M | $6M | $10M |
| Total current assets | $38M | $39M | $124M | $96M | $90M | $51M | $50M | $57M | $65M | $149M |
| Property, plant and equipment | $444,000 | $276,000 | $386,000 | $304,000 | $433,000 | $970,000 | $18M | $23M | $24M | $28M |
| Total assets | $38M | $40M | $125M | $99M | $95M | $56M | $85M | $117M | $125M | $220M |
| Total current liabilities | $22M | $9M | $5M | $29M | $18M | $14M | $12M | $20M | $20M | $24M |
| Total liabilities | $22M | $9M | $5M | $30M | $19M | $15M | $13M | $38M | $27M | $31M |
| Shareholders' equity | $16M | $31M | $120M | $68M | $76M | $41M | $43M | -$16M | $63M | $62M |
| Net debt | -$10M | -$14M | -$31M | -$15M | -$30M | -$44M | -$25M | -$34M | -$12M | -$49M |
Cash flow
Fiscal years, from Gyre Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18M | -$20M | -$29M | -$44M | -$55M | -$84M | $11M | $26M | -$4M | $1M |
| Capital spending | $468,000 | $23,000 | $376,000 | $64,000 | — | $839,000 | $5M | $9M | $2M | $1M |
| Free cash flow | -$19M | -$20M | -$29M | -$44M | — | -$85M | $6M | $17M | -$6M | -$180,000 |
| Stock-based compensation | $635,000 | $863,000 | $3M | $3M | $4M | $3M | $13M | $7M | $831,000 | $7M |
| Dividends paid | — | — | — | — | — | — | $45M | — | — | — |
| Free cash flow margin | — | -1961.0% | -482150.0% | — | — | -1152.8% | 5.6% | 15.3% | -5.6% | -0.2% |
| Dividends per share | — | — | — | — | — | — | $0.59 | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GYRE.
Open GYRE in InvestinglyQuestions
What was Gyre Therapeutics's revenue in 2025?
$117M in fiscal 2025, from its 10-K filing.
How much free cash flow does Gyre Therapeutics generate?
-$180,000 in fiscal 2025 (operating cash flow minus capital spending).
From Gyre Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.